Citigroup has initiated coverage on Agios Pharmaceuticals Inc (AGIO) with a Buy rating, effective November 25, 2025. The current share price stands at $29.04. This marks Citigroup's first assessment of the company, reflecting its analysis of Agios's investment potential in the biotechnology sector.
Agios Pharmaceuticals, headquartered in Cambridge, Massachusetts, focuses on developing transformative therapies for patients with rare diseases. The company employs 486 full-time staff and went public on July 24, 2013. Its lead product, PYRUKYND (mitapivat), is a first-in-class pyruvate kinase (PK) activator aimed at treating hemolytic anemias. Additionally, Agios is advancing other investigational therapies, including tebapivat for lower-risk myelodysplastic syndromes and AG-181 for phenylketonuria.
As of November 1, 2025, the analyst consensus indicates 3 Strong Buy, 7 Buy, and 4 Hold ratings among 14 analysts, suggesting a general positive outlook for the company. Upcoming earnings reports are scheduled for July 29, 2026, with an estimated EPS of -$1.99 and revenue of $22.0 million, following a recent Q3 2025 performance that showed an EPS of -$1.78, surpassing estimates by 8.1%.